Scientists discover new Alzheimer’s drug that repairs DNA damage and reduces brain inflammation — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- KCL-286 reduced DNA double-strand breaks and inflammation in mice with Alzheimer’s-like disease, targeting early biological changes beyond amyloid-beta and tau proteins
- King's College London researchers discovered that KCL-286 activates the retinoic acid receptor-β (RARβ), a pathway linked to vitamin A metabolism and neuronal repair, offering a multi-target approach to Alzheimer’s
- Professor Jonathan Corcoran stated that KCL-286 is a first-in-class, orally bioavailable small molecule that has already passed Phase 1 human safety trials for spinal cord injury, potentially shortening development time for Alzheimer’s use
- Dr. Maria Goncalves emphasized that the drug’s ability to target both DNA damage and inflammation positions it as a potential disease-modifying therapy rather than a symptomatic treatment
- Natasha Hill noted that KCL-286 affects multiple cellular pathways initiated early in Alzheimer’s progression, supporting a shift toward multi-mechanism treatments
- The study was published in FEBS Open Bio on November 2, 2026, and builds on prior findings linking spinal cord injury and Alzheimer’s through shared molecular pathways
Why it matters: Because KCL-286 has already cleared Phase 1 safety trials, drug developers and Alzheimer’s researchers gain a rare head start—potentially cutting years off the timeline to clinical efficacy testing while targeting root biological processes that existing therapies miss.
Ask SkimNews
